Groundbreaking MSF trial finds better treatment for people with drug-resistant tuberculosis
December 21, 2022Findings that prompted WHO to update global DR-TB treatment guidelines now published in the New England Journal of Medicine, show that a much shorter treatment regimen for drug-resistant TB is safer and cured almost 90 percent of patients. A new...
Read more
Tuberculosis: Clinical trial results offer hope to DR-TB patients with short, effective treatment
October 20, 2021LONDON – TB-PRACTECAL, a clinical trial led by Doctors Without Borders/Médecins Sans Frontières (MSF), has found that a new, all-oral, six-month treatment regimen is safer and more effective at treating rifampicin-resistant tuberculosis (RR-TB) [1] than the currently accepted standard of care....
Read more
Tuberculosis: EndTB clinical trial for multidrug-resistant TB completes enrolment
October 18, 2021BOSTON/PARIS — Hundreds of patient volunteers from four continents have enrolled in a trial that aims to find safer, shorter, and effective treatments for multidrug-resistant tuberculosis (MDR-TB), an airborne, infectious disease that has grown resistant to standard medications. A group of scientists and...
Read more
Tuberculosis: Trial of multidrug-resistant TB treatment ends enrolment early after independent board indicates new regimen is superior
March 24, 2021LONDON - A trial aiming to find a better treatment for multidrug-resistant tuberculosis (MDR-TB) has stopped enrolling patients early after its independent data safety and monitoring board indicated that the regimen being studied is superior to current care, and more...
Read more
